Compare Royal Bank of Canada (RY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs Sana Biotechnology Inc — how do they compare? Royal Bank of Canada trades at $191.26 (market cap $262.99B), while Sana Biotechnology Inc trades at $2.85 (market cap $836.71M). The key difference: Royal Bank of Canada is far larger — about 314.3× Sana Biotechnology Inc's market cap, and Royal Bank of Canada pays a 2.66% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royal Bank of Canada for 47 Days and Sana Biotechnology Inc for 23 Days on average.
| RY | SANA | |
|---|---|---|
Market Cap | $262.99B | $836.71M |
Volume | 1,016,377 | 4,507,444 |
Sector | Financials | Health |
52-Week High | $217.87 | $5.92 |
52-Week Low | $143.64 | $2.68 |
Typical Hold Time | 47 Days | 23 Days |
Enterprise Value | $730.11B | $749.96M |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $191.33, up 0.06% on the day, with a bearish technical signal and key support at $189. The company reported strong earnings, beating estimates for three consecutive quarters, with Q3 2026 EPS of $3.07 versus $2.89 expected. Revenue grew to $66.53B in 2025, and net income margin improved to 32.01%. Analyst sentiment is mixed, with 43% buy ratings but technical indicators showing selling pressure.
RY's outlook is supported by solid profitability and dividend payments, but faces risks from stretched valuations and negative cash flow trends. The stock's current bearish technical stance and high debt levels warrant caution, though institutional interest remains. Upside depends on sustained earnings growth and effective cost management amid economic uncertainties.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
